Form 8-K · Current report
Incyte 8-K, filed Aug 31, 2026
- Filed
- CIK
- 0000879169
- Accession no.
- 0000879169-26-000058
Summary
Incyte entered an agreement with the U.S. Centers for Medicare & Medicaid Services under which state Medicaid programs will be able to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced industrialized nations. Incyte said it expects not to be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models, and that the agreement is not expected to affect its 2026 financial guidance or have a material impact on its future financial outlook.
Key points
- The agreement is intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation, according to Incyte.
- State Medicaid programs would gain access to Jakafi and Jakafi XR at prices aligned with a defined group of other advanced, industrialized nations.
- Incyte expects it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models.
- Incyte said it does not expect the agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
From the filing
Item 8.01 Other Events. Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation. Under the agreement, the Company will enable state Medicaid programs to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations. Additionally, the Company expects that it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.